Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.
Girard N, Guisier F, Swalduz A, Van Hulst S, Pichon E, Lavaud P, Greillier L, Tiotiu A, Madroszyk A, Bylicki O, Canellas A, Belmont L, Zysman M, Hauss PA, Godbert B, Audigier-Valette C, Lebreton C, Morin F, Westeel V. Girard N, et al. Among authors: lebreton c. ESMO Open. 2024 Dec;9(12):103968. doi: 10.1016/j.esmoop.2024.103968. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608302 Free PMC article.
Retrospective Multicentric Study on Campylobacter spp. Bacteremia in France: The Campylobacteremia Study.
Tinévez C, Velardo F, Ranc AG, Dubois D, Pailhoriès H, Codde C, Join-Lambert O, Gras E, Corvec S, Neuwirth C, Melenotte C, Dorel M, Lagneaux AS, Pichon M, Doat V, Fournier D, Lemaignen A, Bouard L, Patoz P, Hery-Arnaud G, Lemaitre N, Couzigou C, Guillard T, Recalt E, Bille E, Belaroussi Y, Neau D, Cazanave C, Lehours P, Puges M; Campylobacteremia study group. Tinévez C, et al. Clin Infect Dis. 2022 Sep 10;75(4):702-709. doi: 10.1093/cid/ciab983. Clin Infect Dis. 2022. PMID: 34849656
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
Joly F, Bazan F, Garbay Decoopman D, Ouldbey Y, Follana P, Champeaux-Orange É, Legouffe E, Brachet PE, Spaeth D, Combe P, Hardy-Bessard AC, Selle F, Grenier J, Lebreton C, Derbel O, Bonnet E, Fournel P, Fernandez Diez Y, Delecroix V, Emambux S, Alexandre J, Grellety T, Mille D, Orfeuvre H, Favier C, Le Roux D, Mouret-Reynier MA, Quesada S, Kurtz JE. Joly F, et al. Among authors: lebreton c. JNCI Cancer Spectr. 2024 Dec 14:pkae114. doi: 10.1093/jncics/pkae114. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 39673810
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P. Azaïs H, et al. Among authors: lebreton c. Gynecol Oncol. 2024 Dec 12;192:145-154. doi: 10.1016/j.ygyno.2024.12.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39671779 Free article.
Myosin 1b regulates intestinal epithelial morphogenesis via interaction with UNC45A.
Revenu C, Lebreton C, Cannata Serio M, Rosello M, Duclaux-Loras R, Duroure K, Nicolle O, Eggeler F, Prospéri MT, Stoufflet J, Vougny J, Lépine P, Michaux G, Cerf-Bensussan N, Coudrier E, Perez F, Parlato M, Del Bene F. Revenu C, et al. Among authors: lebreton c. Cell Rep. 2024 Dec 24;43(12):114941. doi: 10.1016/j.celrep.2024.114941. Epub 2024 Dec 4. Cell Rep. 2024. PMID: 39636728 Free article.
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.
Guégan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, Cousin S, Roubaud G, Cabart M, Leroy L, Lebreton C, Rey C, Lara O, Odin O, Brunet M, Vanhersecke L, Gruyters EO, Achour I, Belcaid L, Le Moulec S, Grellety T, Bessede A, Italiano A. Guégan JP, et al. Among authors: lebreton c. Cell Rep Med. 2024 Dec 17;5(12):101831. doi: 10.1016/j.xcrm.2024.101831. Epub 2024 Nov 25. Cell Rep Med. 2024. PMID: 39591972 Free article.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: lebreton c. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
115 results